AR095570A1 - Derivados de urea - Google Patents

Derivados de urea

Info

Publication number
AR095570A1
AR095570A1 ARP140101193A ARP140101193A AR095570A1 AR 095570 A1 AR095570 A1 AR 095570A1 AR P140101193 A ARP140101193 A AR P140101193A AR P140101193 A ARP140101193 A AR P140101193A AR 095570 A1 AR095570 A1 AR 095570A1
Authority
AR
Argentina
Prior art keywords
substituted
cycloalkyl
alkyl
phenyl
pyridinyl
Prior art date
Application number
ARP140101193A
Other languages
English (en)
Inventor
Kuehne Holger
Kuhn Bernd
Neidhart Werner
Obst Sander Ulrike
Richter Hans
Buettelmann Bernd
M Ceccarelli Simona
Conte Aurelia
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR095570A1 publication Critical patent/AR095570A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • C07C273/1863Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety from urea
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302Apparatus specially adapted for immunological test procedures
    • G01N33/5304Reaction vessels, e.g. agglutination plates

Abstract

Reivindicación 1: Compuestos de fórmula (1), en la que: R¹ y R² conjuntamente con el carbono al que se encuentran unidos forman un cicloalquilo; R³ es H, alquilo o cicloalquilo; R⁴ es H, alquilo o cicloalquilo; W es un enlace, -O-, -S-, -NR⁵-, -C(O)-, -S(O)₂-, -C(O)-NR⁵- ó -CR⁶R⁷-; R⁵ es H, alquilo o cicloalquilo; R⁶ y R⁷ se seleccionan independientemente de entre H, alquilo o cicloalquilo; A es fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido, tienopiridinilosustituido, en los que el fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido y tienopiridinilo sustituido se sustituyen con R⁸, R⁹ y R¹⁰; B es cicloalquilo sustituido, cicloalquenilo sustituido, piridinilo sustituido, fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido, tienopiridinilo sustituido, en los que el cicloalquilo sustituido, cicloalquenilo sustituido, piridinilo sustituido, fenilo sustituido, tiofenilo sustituido, benzotiofenilo sustituido y tienopiridinilo sustituido se sustituyen con R¹¹, R¹² y R¹³; R⁸, R⁹, R¹⁰ se selecciona independientemente de entre H, alquilo, alquenilo, alquinilo, hidroxialquilo, haloalquilo, hidroxihaloalquilo, cicloalquilo, cicloalcenil, cicloalquilalquilo, cicloalquenilalquilo, cicloalquilalcoxi, cicloalcoxi, cicloalcoxialquilo, cicloalquilalcoxialquilo, alcoxi, alcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxialquilo, fenilo, fenilo sustituido, piridinilo, piridinilo sustituido, halógeno, hidroxi, ciano, aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido, en los que aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido se sustituyen en el átomo de nitrógeno con uno a dos sustituyentes seleccionados independientemente de entre hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, hidroxialquilo, alcoxialquilo, alquilcarbonilo y cicloalquilocarbonilo, y en los que el fenilo sustituido y el piridinilo sustituido se sustituyen con uno a tres sustituyentes seleccionados de entre alquilo, hidroxialquilo, haloalquilo, cicloalquilo, alcoxi, haloalcoxi, halógeno, hidroxi y ciano; R¹¹, R¹², R¹³ se seleccionan independientemente de entre H, alquilo, alquenilo, alquinilo, hidroxialquilo, haloalquilo, hidroxihaloalquilo, cicloalquilo, cicloalquenilo, cicloalquilalquilo, cicloalquenilalquilo, cicloalquilalcoxi, cicloalcoxi, cicloalcoxialquilo, cicloalquilalcoxialquilo, alcoxi, alcoxialquilo, haloalcoxi, haloalcoxialquilo, alcoxialcoxi, alcoxialcoxialquilo, fenilo, fenilo sustituido, piridinilo, piridinilo sustituido, halógeno, hidroxi, ciano, aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido, en los que aminosulfonilo sustituido, aminocarbonilo sustituido, amino sustituido y aminoalquilo sustituido se sustituyen en el átomo de nitrógeno con uno a dos sustituyentes seleccionados independientemente de entre hidrógeno, alquilo, cicloalquilo, cicloalquilalquilo, hidroxialquilo, alcoxialquilo, alquilcarbonilo y cicloalquilocarbonilo, y en los que el fenilo sustituido y el piridinilo sustituido se sustituyen con uno a tres sustituyentes seleccionados de entre alquilo, hidroxialquilo, haloalquilo, cicloalquilo, alcoxi, haloalcoxi, halógeno, hidroxi y ciano; o sales farmacéuticamente aceptable. Reivindicación 18: Procedimiento para preparar un compuesto según cualquiera de las reivindicaciones 1 a 17, que comprende la reacción de un compuesto de fórmula (2) en presencia de un compuesto de fórmula (3) en el que R¹, R², R³, A, B y W ser tal como se define en la reivindicación 1 y en el que R⁴ es H y Rᵃ es H, NO₂ o F.
ARP140101193A 2013-03-20 2014-03-17 Derivados de urea AR095570A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13160088 2013-03-20

Publications (1)

Publication Number Publication Date
AR095570A1 true AR095570A1 (es) 2015-10-28

Family

ID=47900931

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101193A AR095570A1 (es) 2013-03-20 2014-03-17 Derivados de urea

Country Status (13)

Country Link
US (1) US9278918B2 (es)
EP (1) EP2991967A1 (es)
JP (1) JP6235048B2 (es)
KR (1) KR101804650B1 (es)
CN (1) CN105308020B (es)
AR (1) AR095570A1 (es)
BR (1) BR112015024109A2 (es)
CA (1) CA2898534C (es)
HK (1) HK1214238A1 (es)
MX (1) MX2015013365A (es)
RU (1) RU2642454C2 (es)
TW (1) TWI629258B (es)
WO (1) WO2014146995A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
AU2017341020B2 (en) 2016-10-06 2021-10-28 Daiichi Sankyo Company,Limited Urea derivative
WO2018132533A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
SI3664802T1 (sl) 2017-08-07 2022-10-28 Alkermes, Inc. Biciklični zaviralci histon deacetilaze
CN113401281B (zh) * 2021-08-17 2021-11-02 南通御美津精密工业有限公司 一种船体锚穴外板开口用的关闭装置
WO2023043803A1 (en) * 2021-09-15 2023-03-23 Novius Therapeutics, Llc Fabp4/5 inhibitors, methods of use and methods of making

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
PT1554240E (pt) * 2002-10-21 2009-06-17 Janssen Pharmaceutica Nv Tetralinas e indanos substituídos e sua utilização
US7202269B2 (en) 2003-10-30 2007-04-10 Janssen Pharmaceutica N.V. GlyT2 modulators
FR2869903B1 (fr) * 2004-05-06 2006-06-23 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppary, leur procede de preparation et leur utilisation dans les compositions cosmetiques ou pharmaceutiques
JP4047365B2 (ja) * 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Cxcr2阻害剤
WO2008092878A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2009034062A1 (en) * 2007-09-11 2009-03-19 Glaxo Group Limited Compounds which inhibit the glycine transporter and uses thereof in medicine
EP2358716B1 (en) * 2008-11-12 2016-01-06 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)

Also Published As

Publication number Publication date
TWI629258B (zh) 2018-07-11
US20160002152A1 (en) 2016-01-07
CN105308020B (zh) 2018-01-26
EP2991967A1 (en) 2016-03-09
US9278918B2 (en) 2016-03-08
RU2642454C2 (ru) 2018-01-25
CA2898534A1 (en) 2014-09-25
HK1214238A1 (zh) 2016-07-22
CN105308020A (zh) 2016-02-03
MX2015013365A (es) 2016-01-08
WO2014146995A1 (en) 2014-09-25
KR20150119357A (ko) 2015-10-23
BR112015024109A2 (pt) 2017-07-18
RU2015140599A (ru) 2017-04-26
JP2016514106A (ja) 2016-05-19
CA2898534C (en) 2017-09-19
JP6235048B2 (ja) 2017-11-22
TW201514138A (zh) 2015-04-16
KR101804650B1 (ko) 2018-01-10

Similar Documents

Publication Publication Date Title
AR095570A1 (es) Derivados de urea
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR126406A2 (es) Compuestos de tetrazolinona y su uso
AR098517A1 (es) Compuestos derivados de octahidro-ciclobuta[1,2-c;3,4-c]dipirrol-2-ilo
ES2618703T3 (es) Nuevos compuestos diazaspirocicloalcano y azaspirocicloalcano
AR099823A1 (es) Compuestos bicíclicos de 7 eslabones
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR092645A1 (es) Derivados biciclicos inhibidores de autotaxina (atx)
AR102492A1 (es) Cromanos sustituidos y métodos para su uso
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR088449A1 (es) Benzilindazoles sustituidos
AR096450A1 (es) Compuestos para la modulación de quinasas, y sus indicaciones
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR092838A1 (es) COMPUESTOS TIPO PIRROLO-PIRROLIDINONA COMO INHIBIDORES DE LA INTERACCION ENTRE p53 Y MDM2 Y/O MDM4
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR088625A1 (es) Derivados de aril-quinolina
AR087901A1 (es) Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion
ES2659222T3 (es) 7-azabicíclicos sustituidos y su uso para moduladores de receptores de orexina
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR097866A1 (es) Derivados de 4-azaindol
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina

Legal Events

Date Code Title Description
FB Suspension of granting procedure